( al. Effects of Oral Tolvaptan in Pati...)Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials,Health

Gheorghiade, M, et al., "Short-Term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure: The EVEREST Clinical Status Trials." JAMA 2007;297:1332-1343.

ACC Presentation: 402-7

Session: ACC.07 Late-Breaking Clinical Trials I, Sunday, Mar 25, 2007, 8:30 AM -10:00 AM CST. Presentation Start Time: Sunday, Mar 25, 2007, 8:50 AM CST Effects of Vasopressin Receptor Antagonism With Tolvaptan on Clinical Status, Morbidity and Mortality in Patients Hospitalized With Acute Decompensated Heart Failure: Results of the EVEREST Trial Marvin A. Konstam, Mihai Gheorghiade, John C. Burnett, Jr., Liliana Grinfeld, Aldo P. Maggioni, Karl Swedberg, Faiez Zannad, James E. Udelson, Christopher A. Zimmer, Cesare Orlandi for the EVEREST Investigators.

    (1) Gheorghiade M, Konstam MA, Burnett JC, et al. Short-Term Clinical

        Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients

        Hospitalized for Heart Failure:  The EVEREST Clinical Status Trials.

        JAMA. 2007;297:1332-1343.


    (2) Konstam MA, Burnett JC, Gheorghiade M, et al. Effects of Oral

        Tolvaptan in Patients Hospitalized for Worsening Heart Failure:  The

        EVEREST Outcome Trial. JAMA. 2007;297:1319-1331.


    (3) Rosamond W, Flegal K, Friday G, et al; Heart Disease and Stroke

        Statistics - 2007 Update A Report From the American Heart Association

        Statistics Committee and Stroke Statistics Subcommittee. Circulation.

        2007;115:e69-e171.


    (4) Press Release.  "FDA Approves Astellas' VAPRISOL(R) For The Treatment

        Of Euvolemic Hyponatremia."  Astellas, December 30, 2005.


    (5) Verbalis JG. AVP Receptor Antagonists as Aquaretics: Review and

        Assessment of Clinical Data. Cleveland Clinic J Med 2006;73(3):S24-33.


    (6
'"/>




Page: 1 2 3 4 5 6 7 
Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on
Safety, Tolerability and Glycemic Markers in Subjects With Type 2
Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention
Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and
Long-Term Use of Desvenlafaxine Succinate in the Treatment of
Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain
Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the
Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III
Melanoma Demonstrated Significant and Sustained Impact on
Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators
Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade
Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects
Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing
Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes
for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease